CLINICAL_TRIALS ClinicalTrials.gov record update

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05564390
Title field or adapter rule: {'original_value': 'Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:28.971637+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Source Retrieved At: 2026-10-31T22:18:09.361634+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Acute Myeloid Leukemia, Myelodysplasia-Related", "Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05564390"
protocolSection.identificationModule.officialTitle: "Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)'], 'description': 'Given IV', 'name': 'Allogeneic Hematopoietic Stem Cell Transplantation', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)', 'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)', 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)', 'MM1YA-S01 Arm III (azacitidine, venetoclax)', 'MM2YA-EA01 Arm D (azacitidine, venetoclax)'], 'description': 'Given IV or SC', 'name': 'Azacitidine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)'], 'description': 'Given IV or SC', 'name': 'Azacitidine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'TAP (SOC treatment, mutation carrier screening)'], 'description': 'Receive SOC treatment', 'name': 'Best Practice', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)', 'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)', 'MM2YA-EA01 Arm A (cytarabine)', 'MM2YA-EA01 Arm B (cytarabine, venetoclax)', 'MM2YA-EA01 Arm C (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm D (azacitidine, venetoclax)'], 'description': 'Undergo biopsy', 'name': 'Biopsy Procedure', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-A01 Regimen 1 (ASTX727)', 'MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)', 'MM1MDS-CTG02 Arm 1 (Luspatercept)', 'MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)', 'MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)', 'MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)', 'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)', 'MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)', 'MM1OA-MDS-A05 Cohort C (olutasidenib)', 'MM1OA-S03 Arm 1 (ASTX727, venetoclax)', 'MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)', 'MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)', 'MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)', 'MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)', 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)', 'MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)', 'MM1YA-S01 Arm I (cytarabine, daunorubicin)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)', 'MM1YA-S01 Arm III (azacitidine, venetoclax)', 'MM1YA-S01 Arm IV (Vyxeos)', 'MM1YA-S01 Arm V (Vyxeos, venetoclax)', 'MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)', 'MM3TCT-A03 Maintenance I (venetoclax)', 'MM3TCT-A03 Maintenance II (placebo)'], 'description': 'Undergo collection of blood, urine, and/or buccal swab samples', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-A01 Regimen 1 (ASTX727)', 'MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)', 'MM1MDS-CTG02 Arm 1 (Luspatercept)', 'MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)', 'MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)', 'MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)', 'MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)', 'MM1OA-MDS-A05 Cohort C (olutasidenib)', 'MM1OA-S03 Arm 1 (ASTX727, venetoclax)', 'MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)', 'MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)', 'MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)', 'MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)', 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)', 'MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)', 'MM1YA-S01 Arm I (cytarabine, daunorubicin)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)', 'MM1YA-S01 Arm III (azacitidine, venetoclax)', 'MM1YA-S01 Arm IV (Vyxeos)', 'MM1YA-S01 Arm V (Vyxeos, venetoclax)'], 'description': 'Undergo bone marrow aspiration', 'name': 'Bone Marrow Aspiration', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-A01 Regimen 1 (ASTX727)', 'MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)', 'MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)', 'MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)', 'MM1OA-MDS-A05 Cohort C (olutasidenib)', 'MM1OA-S03 Arm 1 (ASTX727, venetoclax)', 'MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)', 'MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)', 'MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)', 'MM3TCT-A03 Maintenance I (venetoclax)', 'MM3TCT-A03 Maintenance II (placebo)'], 'description': 'Undergo bone marrow biopsy', 'name': 'Bone Marrow Biopsy', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)'], 'description': 'Given IV', 'name': 'Busulfan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)'], 'description': 'Undergo chest x-ray', 'name': 'Chest Radiography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)', 'MM3TCT-A03 Maintenance I (venetoclax)', 'MM3TCT-A03 Maintenance II (placebo)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)', 'MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-S01 Arm I (cytarabine, daunorubicin)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)', 'MM2YA-EA01 Arm A (cytarabine)', 'MM2YA-EA01 Arm B (cytarabine, venetoclax)'], 'description': 'Given IV', 'name': 'Cytarabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)'], 'description': 'Given IV', 'name': 'Daunorubicin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)', 'MM1YA-S01 Arm I (cytarabine, daunorubicin)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)'], 'description': 'Given IV', 'name': 'Daunorubicin Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-A01 Regimen 1 (ASTX727)', 'MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)', 'MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)', 'MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)', 'MM1OA-S03 Arm 1 (ASTX727, venetoclax)', 'MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)', 'MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)', 'MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)'], 'description': 'Given PO', 'name': 'Decitabine and Cedazuridine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)', 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)', 'MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)', 'MM1YA-S01 Arm I (cytarabine, daunorubicin)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)', 'MM1YA-S01 Arm III (azacitidine, venetoclax)', 'MM1YA-S01 Arm IV (Vyxeos)', 'MM1YA-S01 Arm V (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm A (cytarabine)', 'MM2YA-EA01 Arm B (cytarabine, venetoclax)', 'MM2YA-EA01 Arm C (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm D (azacitidine, venetoclax)', 'MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)'], 'description': 'Undergo ECHO', 'name': 'Echocardiography Test', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)'], 'description': 'Given PO', 'name': 'Emavusertib', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)', 'MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)'], 'description': 'Given PO', 'name': 'Enasidenib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)'], 'description': 'Given SC', 'name': 'Epoetin Alfa', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)'], 'description': 'Given IV', 'name': 'Fludarabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)'], 'description': 'Given IV', 'name': 'Gemtuzumab Ozogamicin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)'], 'description': 'Given PO', 'name': 'Gilteritinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-S01 Arm IV (Vyxeos)', 'MM1YA-S01 Arm V (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm C (Vyxeos, venetoclax)'], 'description': 'Given IV', 'name': 'Liposome-encapsulated Daunorubicin-Cytarabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1MDS-CTG02 Arm 1 (Luspatercept)', 'MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)', 'MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)'], 'description': 'Given SC', 'name': 'Luspatercept', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)'], 'description': 'Given IV', 'name': 'Melphalan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)', 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)', 'MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)', 'MM1YA-S01 Arm I (cytarabine, daunorubicin)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)', 'MM1YA-S01 Arm III (azacitidine, venetoclax)', 'MM1YA-S01 Arm IV (Vyxeos)', 'MM1YA-S01 Arm V (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm A (cytarabine)', 'MM2YA-EA01 Arm B (cytarabine, venetoclax)', 'MM2YA-EA01 Arm C (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm D (azacitidine, venetoclax)', 'MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Maintenance I (venetoclax)'], 'description': 'Undergo MUGA', 'name': 'Multigated Acquisition Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Screening (mutation carrier screening)', 'TAP (SOC treatment, mutation carrier screening)'], 'description': 'Undergo rapid genetic testing', 'name': 'Mutation Carrier Screening', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)', 'MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)', 'MM1OA-MDS-A05 Cohort C (olutasidenib)'], 'description': 'Given PO', 'name': 'Olutasidenib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)', 'MM3TCT-A03 Maintenance II (placebo)'], 'description': 'Given PO', 'name': 'Placebo Administration', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 1B (matched donors with placebo)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)', 'MM3TCT-A03 Maintenance I (venetoclax)', 'MM3TCT-A03 Maintenance II (placebo)'], 'description': 'Undergo PET', 'name': 'Positron Emission Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)'], 'description': 'Given PO', 'name': 'Quizartinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)'], 'description': 'Undergo total body irradiation', 'name': 'Total-Body Irradiation', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)', 'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)', 'MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)', 'MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)', 'MM1OA-S03 Arm 1 (ASTX727, venetoclax)', 'MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)', 'MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)', 'MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)', 'MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)', 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)', 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)', 'MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)', 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)', 'MM1YA-S01 Arm III (azacitidine, venetoclax)', 'MM1YA-S01 Arm V (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm B (cytarabine, venetoclax)', 'MM2YA-EA01 Arm C (Vyxeos, venetoclax)', 'MM2YA-EA01 Arm D (azacitidine, venetoclax)', 'MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)', 'MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)', 'MM3TCT-A03 Maintenance I (venetoclax)'], 'description': 'Given PO', 'name': 'Venetoclax', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.